Research programme: drug discovery - Evotec/Genentech

Drug Profile

Research programme: drug discovery - Evotec/Genentech

Latest Information Update: 27 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evotec AG; Genentech
  • Class Pyrazoles; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Unspecified

Most Recent Events

  • 24 May 2016 Preclinical development is ongoing in Germany
  • 24 May 2016 Evotec and Genentech extend drug discovery alliance for three years
  • 22 Apr 2013 Evotec and Genentech agree to extend drug discovery alliance for a further three years
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top